How every figure is sourced, dated, and computed
GLPcompare exists to be trusted. Every price, status, and research count on this site traces to a named public record, carries a confidence tier, and is stamped with when we retrieved it. This page is the full account of how that works, so you never have to take a number on faith.
What a confidence dot means
Every figure carries one of four tiers. The dot's color is the same on every surface, so a claim's KIND is always legible at a glance. Color is never used alone: a text label always accompanies it.
Direct from an authoritative FDA, NLM, or CMS source.
Published by the manufacturer about its own product.
From a reputable secondary source.
Derived by GLPcompare from primary sources; shown with a leading ~.
Editorial as-of vs live retrieval
A health-data site fails the moment it presents a stale figure as current. We keep two clocks and never let one stand in for the other.
The curated, code-owned catalog (drug and supplement identity, mechanisms, the source registry, this copy) is dated as of Sep 30, 2026. It changes only when the code is edited, and it is never shown next to a live number.
Every live figure (price, shortage, trial, recall) carries its own fetched_at and reads as retrieved X ago. Right now the board shows:
A verified figure whose feed has not refreshed within its cadence is visibly downgraded and labeled “May be stale” rather than shown as confidently live. A broken pipeline surfaces as stale, never as silence.
The curated catalog was last reviewed Sep 30, 2026; the next scheduled full review is Oct 16, 2026.
Recent updates to the data
A dated record of material changes to the curated catalog, so you can see the reference is actively maintained, not frozen.
Rechecked 54 of the 58 cash quotes on the sellers' own pages (Ro's and Hims' pages could not be reached; their September 26 checks stand), and every quote now carries its own check date. Eden's compounded tirzepatide is now a flat $129/mo (was $249, then $329); Mochi's medication now starts at $60 (semaglutide) and $90 (tirzepatide) plus membership; Noom's recurring price rose to $279/mo; Strut's injectable tirzepatide is $149 per 30 days; Gala starts at $179/mo on a yearly plan; Found now publishes product prices (from $169 and $239 per 28 days on a 12-month plan). Sprout's and Wellorithm's advertised prices were first-month discounts and Ozari's $86 and $125 are a one-time three-month starter plan, so each now shows its recurring terms. GoodRx's liraglutide listings are generics, and TrumpRx now issues a pharmacy coupon. The catalog's review date is now the oldest individual quote check.
Updated the drug catalog: Rybelsus is being replaced by Ozempic tablets; brand Saxenda is leaving the US (last shipments expected January 2027); tirzepatide's heart-failure (HFpEF) indication is EU-only, as Lilly withdrew its US application in 2025; pemvidutide is now a liver-disease program; amycretin is now named zenagamtide; added retatrutide's published TRIUMPH-2 results and aleniglipron's 72-week data. Semaglutide's FDA status now reads 'No shortage reported' with its planned Rybelsus discontinuations listed, instead of 'unknown'. Merged duplicate category pages (three 'obesity' pages into one, three 'MASH' pages into one) and redirected their old addresses.
Corrected the Medicare policy-price interpretation in earlier updates. Bridge now shows the eligible patient's copay and covered formulations; negotiated prices identify the exact CMS package instead of a general monthly cost. Separated upcoming manufacturer list prices, added source-review dates, and removed international price ratios that mixed reporting years. The full-catalog review date is unchanged.
How each live column is built
Source records and computed indexes are labeled separately. Publication counts describe research activity; trial results describe what was measured.
Acquisition cost
VerifiedThe acquisition-cost figure is the National Average Drug Acquisition Cost (NADAC) per unit: the average price pharmacies actually pay to buy the drug, published weekly by CMS. It is a neutral cost benchmark, not the cash price you pay at the counter, and not a manufacturer list price. We select one complete weekly release from the CMS annual archive and retain its release date, rate effective date, product code (NDC), pricing unit and exact source link. A failed or incomplete refresh keeps the previous release with its original check date. Products absent from a newer complete release leave the current comparison. Price-history charts use only observations from validated releases, matching the same NDC and pricing unit throughout. Manufacturer self-pay and savings-program prices are shown separately and marked as Stated, because they are published by the maker about its own product. Cash comparisons retain published supply periods and known upfront commitments. A 28-day supply is four weeks, not a calendar month; an annual-plan monthly rate is not the amount due each month. Cost ordering divides a quoted amount by its documented days of supply and multiplies by 30. For example, $399 for 28 days is approximately $427.50 per 30 days. This comparison rate is not an invoice, a calendar-month bill, or a forecast of treatment cost. Cash quotes carry individual review dates. Quotes not checked within the past 21 calendar days, or with an invalid or future review date, remain dated references and receive no cost rank or price score. This review window is our editorial policy, not a claim that an offer has expired. A review of one offer never refreshes another, and maintenance quotes can have their own review dates. Prices with an unknown supply period or separate medication and service billing cycles also stay visible but receive no cost rank. Supply periods are never inferred from the word monthly. Introductory rates are not projected beyond their terms. A general program starting price is excluded when it cannot be attributed to the named product.
The source registry
Every fact on the site names one of these sources. A Primary mark means the source is free, open, and updated at least daily: the drivers behind the live board.
Identity, labeling & safety
Submitted structured product labels: product identity, source version, indications, dosing, warnings, contraindications, interactions and adverse reactions.
U.S. Food & Drug Administration
Neutrality, and the caveats we never hide
GLPcompare compares by the underlying data (price, shortage status, evidence), and a partner never changes a price or a fact. Partner status and commission rates contribute to offer and provider value scores and can affect their order. Every partner is labeled. A value score is not a medical recommendation or a guarantee of the lowest price. We show a figure only when we have a real source for it; when we do not, we show an honest gap, never an invented number.
Authorship and expertise
Every figure on GLPcompare is drawn from primary sources (the FDA, the U.S. National Library of Medicine, CMS, and the NIH Office of Dietary Supplements) and links back to the record that proves it. Literature counts link to the exact Europe PMC searches and describe research activity, not evidence quality. We publish what the sources say, cite where it came from, and stamp when we retrieved it.